Compare LODE & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LODE | NYXH |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.1M | 188.1M |
| IPO Year | N/A | 2021 |
| Metric | LODE | NYXH |
|---|---|---|
| Price | $3.48 | $4.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $4.00 | ★ $12.67 |
| AVG Volume (30 Days) | ★ 828.9K | 48.0K |
| Earning Date | 10-30-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,778,445.00 | ★ $6,616,215.00 |
| Revenue This Year | N/A | $79.25 |
| Revenue Next Year | $1,798.62 | $297.08 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 48.99 | 10.96 |
| 52 Week Low | $1.67 | $4.35 |
| 52 Week High | $10.10 | $11.87 |
| Indicator | LODE | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 53.34 | 44.65 |
| Support Level | $3.19 | $4.69 |
| Resistance Level | $3.70 | $4.90 |
| Average True Range (ATR) | 0.26 | 0.20 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 54.03 | 41.18 |
Comstock Inc innovates and commercializes technologies that are deployable across entire industries to contribute to energy abundance by efficiently extracting and converting under-utilized natural resources, such as waste and other forms of woody biomass into renewable fuels, and end-of-life electronics into recovered electrification metals. Comstock's innovations group is engaged in developing and using artificial intelligence technologies for advanced materials development.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.